Metastatic breast cancer affects long-term survival and is a major cause of cancer death for women worldwide. The Metalloprotease-Disintegrin ADAM8 promotes breast cancer development and brain metastasis in a mouse breast cancer model. Here, abundant ADAM8 expression was detected in primary human breast tumors and associated brain metastases. To investigate the function of ADAM8 in metastasis, MB-231 breast cancer cells with ADAM8 knockdown (MB-231_shA8) and scramble control cells (MB-231_shCtrl) were analyzed for their capability to develop metastases. In vitro, formation of metastatic complexes in hanging drops is dependent on ADAM8 and blocked by ADAM8 inhibition. MB-231_shA8 in contrast to MB-231_shCtrl cells were impaired in transmigration through an endothelial and a reconstituted blood-brain barrier. Out of 23 MMP and 22 ADAM genes, only the MMP-9 gene was affected by ADAM8 knockdown in MB-231_shA8 cells. Following reexpression of wild-type ADAM8 in contrast to ADAM8 lacking the cytoplasmic domain in MB-231_shA8 cells caused increased levels of activated pERK1/2 and pCREB (S133) that were associated with elevated MMP-9 transcription. Application of ADAM8 and MMP-9 antibodies reduced transmigration of MB-231 cells suggesting that ADAM8 affects transmigration of breast cancer cells by MMP-9 regulation. ADAM8-dependent transmigration was confirmed in Hs578t cells overexpressing ADAM8. Moreover, transmigration of MB-231 and Hs578t cells was significantly reduced for cells treated with an antibody directed against P-selectin glycoprotein ligand (PSGL-1), a substrate of ADAM8. From these data we conclude that ADAM8 promotes early metastatic processes such as transendothelial migration by upregulation of MMP-9 and shedding of PSGL-1 from breast cancer cells.
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Breast carcinoma is the most frequent malignancy and second most common cause of cancer-related death in women worldwide. 1 Long-term survival remains unfavorably affected due to the high risk that breast cancer cells metastasize into distant organs, predominately the bones, the lungs and the brain. 2 Metastatic cancer spread is the cause of death in 90% of cancer patients 3 and brain metastases occur in 10-16% of breast cancer patients. Since brain metastases are critical for survival of patients, 2 unraveling the molecular mechanisms of metastasis formation is of great importance for potential therapeutic intervention.
Metastasis is a multistep process that requires uncontrolled tumor growth with penetration of the basement membrane and neo-angiogenesis. 4 New blood vessels growing into the primary tumor cell mass allow malignant cells to detach and to enter the circulation. In the blood stream, circulating tumor cells extravasate into distant organs by penetrating the endothelium 5 or, in case of brain metastases, the blood brain barrier in order to form small colonies in the target organ that survive apoptotic clues and finally regrow at the secondary side. [4] [5] [6] Multiple steps of the metastatic cascade require proteolytic activity, 7 mechanistically, besides matrix remodeling and degradation, proteases cleave adhesion molecules, shed growth factors and activate kinases. [7] [8] [9] Disseminated tumor cells in the bloodstream enter the target organ using mechanisms similar to leukocyte rolling on the luminal surface of the vascular wall which is propagated on the endothelial side by a class of carbohydrate binding proteins such as E-and P-Selectins 10 whose counterparts are the ligands ESL-1, CD44 and PSGL-1. 11, 12 Similar to leukocytes, circulating tumor cells express these selectin ligands on their surface. 13 Thus, processing of these ligands on the cell surface, as performed by sheddases, 14 regulates the balance between adhesion and mobility of circulating tumor cells. Following tethering, intraluminal crawling and finally firm adhesion to the endothelial layer, endothelium-attached tumor cells can proliferate and build intravascular tumor microcolonies as metastatic seeds 15 or they extravasate by inducing necroptosis of endothelial cells via APP and DR6. 16 Shedding enzymes are Matrix Metalloproteinases (MMPs), and membrane-typed MMPs (MT-MMPs) both members of the metzincin superfamily, as well as MetalloproteaseDisintegrins, termed ADAM (A Disintegrin and Metalloprotease) proteinases. For proteolytic processing of the above ligands, several MMPs and ADAM protease family members have been described. ESL-1 is cleaved by a so far unknown metalloprotease and shedding of ESL-1 in microglia cells and macrophages is induced by lipopolysaccharide.
17 CD44, the hyaluronic acid receptor, can be cleaved by MT-MMP1 18 and by ADAM10. 19 The P-selectin ligand PSGL-1 can be cleaved by ADAM8, which was demonstrated initially in zebrafish (Danio rerio) where a lack in ADAM8 caused a delay in the onset of blood circulation, due to firm adhesion of leukocytes to endothelial cells of the vasculature. 20 Thus, the major effect caused by shedding of selectin ligands is an increase in mobility and invasiveness into tissues or epithelia. 21 By interacting with cellular integrins, ADAM proteases can co-cluster in cell protrusions and mediate barrier function by active proteolysis. 22 In addition, integrin-mediated signals can enhance extracellular activities of matrix metalloproteases. 23 MMPs furthermore promote a loss of the integrity of the basement membrane and allow direct invasion of carcinoma cells via proteolytic breakdown of tight junctions and extracellular matrix proteins. 24, 25 In this context, MMP-9 promotes transendothelial migration 24 and it is likely that regulation of MMP-9 together with de-adhesion of tumor cells from the endothelium is essential for the metastatic process.
Recently, the metalloprotease-disintegrin ADAM8 has been described in the context of PSGL-1 shedding 26 and in dissemination of breast cancer cells. 27 High expression levels of ADAM8 are associated with increased numbers of circulating tumor cells and consequently with higher frequencies of brain metastases in orthotopic mouse models. 27 Here we investigated ADAM8 expression in brain metastases from different primary lesion sites and show that ADAM8 is increased in brain metastases from primary breast cancer and facilitates transmigration through endothelium and blood-brain barriers. Furthermore we demonstrate that the observed proteolytic effect of ADAM8 is due to upregulation of MMP-9 expression and activity. We provide mechanistic evidence for a regulation of MMP-9 expression by ADAM8-mediated signaling in breast cancer cells, supporting the notion that metalloproteases can regulate each other in cross-talks, known as the "Protease Web." 28 
Material and Methods

Antibodies and reagents
For detection of human antigens in western blots, immunostainings and for blocking experiments, polyclonal antibodies against the ectodomain of ADAM8 (AF-1031) and human MMP-9 (AF911) were obtained from R&D Systems (Abingdon, UK). An antibody against the cytoplasmic domain of ADAM8 (AB19017) was purchased from Millipore (Watford, UK). The b1 integrin blocking antibody (AIIB2) was a kind gift from Dr. N. Cordes, Oncoray Dresden, Germany. To determine phosphorylation of multiple kinases, Proteome Profiler Human Phospho-MAPK Array Kit (ARY002, R&D Systems) was used, specific antibodies against the phosphorylated forms of ERK1/2 (T202/Y204) and CREB (S133) were obtained from Cell Signaling (Hitchin, UK). Horseradish peroxidase (HRP) conjugates antibodies were purchased from Abcam and R&D Systems. Human sPSGL-1 Platinum ELISA was purchased from affymetrix ebioscience (now Thermofisher Scientific, Dreieich, Germany). BB-94 (batimastat) and BB-2516 (marimastat) were purchased from Tocris (Biotechne, Wiesbaden, Germany) and dissolved in DMSO to prepare 1000-fold stock solutions. When inhibitors were used in cell culture, DMSO vehicle controls were included.
Cells
MDA-MB-231 and Hs578t (both triple-negative) mammary breast cancer cells were purchased from American Type Culture Collection (ATCC). MB-231 cells were grown in DMEM (Dulbecco's-modified Eagle medium, Invitrogen, Groningen, The Netherlands), with media containing 10% fetal calf serum, 1% penicillin/streptomycin and 1% glutamine (Invitrogen, UK). Hs578t cells were grown in RPMI medium containing 10% fetal calf serum, 1% penicillin/streptomycin and 1% glutamine. For all experiments, cells were kept in humidified atmosphere at 378C/5% CO 2 .
Generation of stable MDA-MB-231 ADAM8 knock-down cells MDA-MB-231 cells were transfected with four shADAM8 constructs (TF314948, Origene; target sequence 5 0 -GCGGCACCTGCATGACAACGTACAGCTCA 23 0 ) cloned in pRFP-C-RS vector using Lipofectamine LTX (Invitrogen, UK). Twenty-four hours after transfection, cells were treated with the respective selection antibiotic (1 mg/ml puromycin). Around 20 cell clones were selected and checked for successful knockdown of ADAM8. To generate control cell clones, a construct with a scramble shRNA (target sequence 5 0 -GCACTACCAGAGCTAACTCAGATAGTACT -3 0 ) sequence was used. ADAM8 expression in single cell clones was analyzed by qRT-PCR, western blotting and ELISA.
Generation of stable ADAM8-expressing Hs578t cell clones
Hs578t cells were transfected either with an origene vector expressing full-length ADAM8 under control of the CMV promoter (Hs578t_A8) or with an empty vector (Hs578t_Ctrl). After selection of resistant cell clones using G418 (1 mg/ml), one representative cell clone with a moderate overexpression of ADAM8 was used for subsequent analyses. Expression of ADAM8 in stable cell lines was confirmed by western blot.
Human samples
Prior to the study informed consent was obtained from patients to use their surgical specimen and clinicopathological data for research purposes according to the guidelines of the local Ethics committee at Medical Faculty of Marburg University (File number 185/11 and amendment). Surgical tissues were snap-frozen in liquid nitrogen immediately after resection and stored at 2808C.
Immunohistochemistry
For immunostains, 3 mm sections of paraffin-embedded patient specimen from formalin-fixed tumors were deparaffinized with xylene and rehydrated through an alcohol gradient. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide. Sections were incubated with a primary antibody targeting ADAM8 (1:150, AF1031) on an automated immunostainer using a labeled streptavidin-biotin method (Dako, Hamburg, Germany) followed by 3,3 0 -diaminobenzidine chromogen detection. Immunostained slides were counterstained with hematoxylin. Negative controls were included in each run by omitting the primary antibody. ADAM8 immunoreactivity in carcinomatous cells was scored by a pathologist according to the immunoreactive score (IRS), see supplement for details. Images were captured and exported with NIS Elements software (Nikon) and presented as TIF files.
Quantitive real-time PCR
Total RNA from tissue samples and cell lines was isolated using peqGold Total RNA Kit (VWR, Randnor, Pennsylvania) according to the manufacturers protocol. After reverse transcription of 1 mg total RNA (Clontech, Saint-Germainen-laye, France), quantitative PCR (qPCR) was performed using SYBR green kits (PrimerDesign, Southhampton, UK) in a STEP-One Light cycler (ABI Systems, Weiterstadt, Germany). cDNA equivalent of 20 ng total RNA for each sample was used in 20 ml PCR reaction volume containing PrecisionPlus 23 qPCR Mastermix, forward and reverse primers. The geNorm algorithm was used to determine the most stable reference genes in the sample panel. Gene expression levels were averaged among three technical replicates and normalized to the average of two reference genes, ACTB and GAPDH (PrimerDesign, Southhampton, UK). Relative changes in gene expression were determined with the DCt method.
Cycling parameters were: initial denaturation: 958C, 2 min followed by 40 
Western blot
For whole cell lysates, dissected tissue samples or tumor cells were homogenized in RIPA buffer (50 mM HEPES pH 7,4, 150 mM NaCl, 1% NP-40, 0,5% Natriumdeoxycholat, 0,1% SDS, 10 mM Phenanthrolin) with Inhibitor tablets complete w/o EDTA and PhosSTOP (Roche, Basel, Switzerland) using a dispenser (T10 Ultra-Turrax, Ika, Staufen, Germany). 5 3 Laemmli buffer (0.2 M TrisHCl, pH 6.8, 20% glycerol, 10% SDS, 10 mM b-mercaptoethanol) was added and samples were denatured at 958C for 10 min previous to electrophoresis. Equal amounts of protein were loaded onto 10% reducing polyacrylamide (PAA) gels. The proteins were transferred on nitrocellulose membranes and unspecific binding sites were blocked (5% skimmed milk, 0.1% Tween-20 in PBS). Detection of target proteins was performed using specific antibodies (ADAM8: 1:1,000, MMP-9: 1:2,000, pERK1/2: 1:2,000). As secondary antibodies, HRP-conjugated (Horseradish peroxidase) antibodies were used in dilutions of 1:2,000, respectively (anti-goat-HRP and antirabbit-HRP, Abcam, Cambridge, UK) in conjunction with chemiluminescent substrate (Super Signal TM West Pico, Thermo Scientific, Bonn, Germany). Chemiluminescence was determined
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(Intas, Chemostar Imager) and quantified by Image J (NIH, Maryland).
Gelatine zymography
Samples were prepared in non-reducing sample buffer without boiling before the experiment. Gelatin (0.1%) was added in a separating gel to co-polymerize with PAA. Prior to loading the gels, samples were either incubated with 2 mmol/ l aminophenylmercuric acetate (APMA; Sigma, Munich, Germany) for 2 hrs at 378C or left untreated to detect MMP pro-and active form. During electrophoresis, proteins are separated in the PAA gel, while SDS present in the gel preserves MMPs in an inactive state. After the run, gels were washed with renaturing buffer (2.5% Triton X-100; 2 3 30 min each) that resulted in partially renatured MMPs with restored activity. The gel was incubated in developing buffer (50 mM Tris, pH 7.5, 200 mM NaCl, 4 mM CaCl 2 and 0.02% Brij-35; 30 min at RT, followed by 24 hrs at 378C in fresh developing buffer). Next day, the gel was dyed in Coomassie staining buffer for 1 hrs followed by destaining solution to visualize bands of active enzyme.
Determination of MMP/ADAM activities in cell supernatants
For analysis of protease activities in cell supernatants, MDA-MB-231 cells were cultured in duplicate using a six-well plate. Confluent cell layers were incubated for 24 hrs in serum-free DMEM medium without phenol red. Medium was removed, spun to remove debris, 103 concentrated using Vivaspin columns (MWCO 10,000) and set aside for assaying. Supernatants were tested for MMP/ADAM activity by using the PrAMA analysis technique developed by Miller et al. 29 using FRET-polypeptide substrates PEPDab005, PEPDab008, PEPDab010, PEPDab13 and PEPDab14, which varied in their specificities towards different ADAMs and MMPs. Briefly, 10 mM substrate concentrations in 50 ml assay buffer (1 mM ZnCl 2 , 20 mM Tris-HCl pH 8.0, 10 mM CaCl 2 , 150 mM NaCl, 0.0006% Brij-35) were incubated with 50 ml 103 concentrated cell supernatants. Fluorescence units versus time were monitored with a Fluostar BMG Optima using excitation and emission wavelength of 485 and 530 nm, respectively. Specific protease activities were inferred with PrAMA by comparing the pattern of substrate cleavage rates for each sample to a matrix of known substrate specificities for defined ADAMs and MMPs using the Software Matlab (2014b). 29, 30 Each PrAMA experiment was repeated three times and values for activities are given as relative to defined shCtrl measurements.
BBB model co-culture Transwell TM system
A co-culture BBB-model comprising Porcine Brain Endothelial Cells (PBEC) and primary rat astrocytes following the method of Abbott et al. 31 was used to evaluate the transmigration of MB-231 cells across the BBB. Briefly, primary astrocytes were cultured into a 12-well plate coated with 10 mg/ml poly-L-Lysine one week before the experiment. PBECs were initially grown in T-75 flasks and sub-cultured onto 8,0 mm Transwell TM filters. When cells reached 50% confluency, the Transwell TM filters containing PBECs were placed in the wells above the astrocytes. The trans-endothelial electrical resistance (TEER) was measured (EVOM epithelial Volt/ Ohm Meter, World Precision Instruments, UK) to assess the tightness of the BBB model, transmigration studies were performed when TEER was >200 Xcm 2 .
Lentiviral transduction
shRNA targeting ADAM8 was inserted into the lentiviral expression vector pLVTHM (plasmid #12247, Addgene), targeting sequences were as follows:
0 (scramble control). For preparation of recombinant lentiviral particles, subconfluent HEK293T cells were cotransfected with 10 lg of the specific LVTHM-plasmid, 7.4 lg of psPAX2 (plasmid #12260, Addgene) and 2.6 lg of pMD2G (plasmid #12259, Addgene) using 4 ll/ml polybrene (Sigma, Munich, Germany). 24 hrs after transfection, the medium was exchanged and after another 48 hrs of incubation the supernatants containing lentiviral particles were harvested. Supernatants were concentrated 5003 by ultracentrifugation at 50,000g for 2 hrs and resuspended in PBS. For lentiviral transduction, 2 ll lentivirus concentrate in 1 ml DMEM with polybrene 4 lg/ml were subjected to 2 3 10 5 breast cancer cells, transduction efficiency was controlled by GFP expression encoded by pLVTHM.
Transendothelial migration assay
To evaluate transendothelial migration, 1.5 3 10 4 Human Umbilical Vein Endothelial Cells (HUVEC) were subcultured onto 8,0 mm Transwell TM filters (#CLS3464, Corning TM ) precoated with Fibronectin. After 24 hrs of incubation, 2 3 10 5 MDA-MB-231 cells in 100 ml RPMI medium (0,1% BSA, 25 mM HEPES) were added to the upper compartment and transmigration through the endothelial barrier was stimulated bei adding SDF-1a (10 ng/ml) to the lower compartment. Breast cancer cells were allowed to transmigrate for 12 hrs, filters were fixed with 4% paraformaldeyde and cells remaining on the upper surface were removed using a cotton swab. Transmigrated GFP-labeled tumor cells were quantified using ImageJ (NIH, Maryland).
For functional experiments, breast cancer cells were preincubated for 2 hrs with 20 mg/ml monoclonal blocking antibodies against specific target proteins (MAB PSGL-1, PromoCell; MAB1031 ADAM8, R&D Systems) or control IgG, respectively.
Tumor sphere assays
For spheroid generation, single-cell suspensions in complete media with 2,5% matrigel were plated at densities of 5 3 10 attachment 96-well plates (Corning B.V. Life Sciences, Amsterdam, The Netherlands) using a multichannel pipette. Plates were incubated for 4 days at 378C, 5% CO 2 , 95% humidity. For visualization of tumor spheres, cells were stained with 10 mM Calcein (PromoCell, Heidelberg, Germany). An inverted microscope (Leica) equipped with a CCD camera was used for documentation.
Statistical Analysis
Student's t test and the one-way ANOVA were employed for statistical analysis. Based on the obtained results, the data was considered not significant (p > 0.05), significant * (p < 0.05), highly significant ** (p < 0.01), or very highly significant *** (p < 0.001). Data are expressed as the mean 6 SD.
Results
ADAM8 is highly expressed in human brain metastases
ADAM8 expression levels in brain metastases arising from different primary tumors were analyzed by real-time qPCR, western blot and immunohistochemistry. Metastases specimens were derived from breast cancer (BC, n 5 10), non-small cell lung carcinoma (NSCLC, n 5 9), small cell lung carcinoma (SCLC, n 5 3), and malignant melanoma (MM, n 5 7). As control tissue, normal brain tissue was classified as non-tumor access tissue from epilepsy surgery (crtl, n 5 5). All brain metastases showed increased levels of ADAM8 mRNA as compared to normal brain tissue. In particular, breast cancer derived metastases were 11.7-fold, SCLC metastases 41.5-fold, NSCLC metastases 18.8-fold and metastases from malignant melanoma 80.2-fold higher for ADAM8 expression levels (Fig. 1a) . In brain metastases, ADAM8 protein levels were determined by Western Blots (Figs. 1b and 1c) . Quantification of ADAM8 bands and densitometric analysis using ImageJ (NIH, Maryland) revealed increased ADAM8 protein levels in BC (12.9-fold), SCLC (9.0-fold), NSCLC (8.9-fold), and in MM metastases (3.1-fold, Fig.  1b ) compared to normal brain control tissue. ADAM8 protein levels were highest in BC metastases, in contrast to the mRNA analysis, probably due to a higher cytoplasmic/nucleus ratio seen in cells of BC metastases compared to metastatic cells from SCLC and NSCLC. In a representative specimen, surgical access tissue was compared to metastastic tissue in the same patient and revealed a difference in ADAM8 expression levels, suggesting that ADAM8 is highly accumulated in metastases (Fig. 1c) .
All metastases were subjected to immune-staining using anti-ADAM8 antibody (Fig. 1d) . On the cellular level, strong ADAM8 staining was detected in the cytoplasm as vesicular structures and in the plasma membrane, in accordance with ADAM8 as a transmembrane protein (Fig. 1e) . The neoplastic stroma remained negative in all specimens analyzed.
For seven cases of metastases from breast cancer, we were able to backtrack primary BC tumor to analyze ADAM8 expression levels (Immune reactivity Score provided as Supporting Information Fig. S1 ) and the clinicopathological data (Table  1) . In all cases of primary breast cancer with associated brain metastases (n 5 7), ADAM8 expression was sustained when primary tumors were positive for ADAM8. In a larger number of breast cancer tumor specimens including those seven cases (n 5 19) a strong staining for ADAM8 was seen by immunhistochemistry in the invasion zone (Supporting Information Figs. S2b and S2c), suggesting that ADAM8 could contribute to intravasation of tumor cells in accordance with increased numbers of CTCs derived from ADAM8
1 MB-231 cells. 27 In total, 75% of all metastases investigated (n 5 44) were ADAM8 positive (Supporting Information Fig. S2a ). In these metastases, ADAM8 staining was seen either in the entire metastase (47.7%) or in focal areas (27.3%).
ADAM8 expressing MB-231 breast cancer cells show high metastatic potential
To test the metastatic potential of cells expressing ADAM8 in vitro, MB-231 cells were generated with a stable knockdown of the ADAM8 gene. 27 Two MB-231 cell clones stably transfected with a scramble shRNA sequence served as controls (shCtrl-3 and shCtrl-5) and two representative knockdown cell clones (shA8-17 and shA8-20) were used for the analysis. A significant knockdown of ADAM8 gene transcription in MB-231_shA8 cells was confirmed on the mRNA (Fig. 2a) , the protein level (Fig. 2b) , and, furthermore, by ELISA detecting the amount of soluble ADAM8 released from MB-231 cells (Fig. 2c) . In addition, microarray analysis of MB-231_shCtrl and MB-231_shA8 cell clones excluded off-target effects of the knockdown (data not shown). Cell morphology in MB-231_shA8 cells is different from that of MB-231_shCtrl cells, with less formation of lamellipodiae and smaller cell areas (Fig. 2d) .
By hanging drop spheroid assays, MB-231 cells were analyzed for their tendency to aggregate, which is a measure for colonization, a major step in the formation of macrometastases (Figs. 2e and 2f) . After 20 hrs, MB-231 control cell clones (shCtrl-3 and shCtrl-5) have formed a considerable amount of spheres of up to 150 lm diameter, whilst spheres are small or even absent from shA8 cell clones (shA8-17 and shA8-20). Next, we investigated if pharmacological inhibition of ADAM8 affects sphere formation similar to the genetic knockdown. The cyclic peptide ADAM8 inhibitor BK-1361 32 was used in a concentration range of 50-1,000 nM (Fig. 2f) . Compared to inactive control peptide (CP), BK-1361 prevented sphere formation significantly at 500 and 1,000 nM.
ADAM8 mediates transmigration through an endothelial barrier
Transmigration assays were performed to test the ability of transmigration through a layer of HUVEC cells dependent on the ADAM8 dosage (Fig. 2g) . MB-231 cells were transduced with either a control ("shScramble") virus particle or a lentivirus bearing two different target sequences for successful ADAM8 knockdown (shA8_903 and shA8_1831). Chemotaxis was induced by stromal cell derived factor SDF-1/CXCL12 in the lower chambers and transmigration was determined by counting cells present at the lower membrane. Less cells were detected in ADAM8 kd cells compared to scramble control cells ( Fig. 2g) suggesting that ADAM8 promotes transendothelial migration of MB-231 cells.
Transmigration through an in vitro BBB model
Since brain metastasis requires transmigration through the BBB as a more specialized endothelium in the brain, we further investigated in an organotypic BBB model if ADAM8 can also promote transmigration through a BBB barrier in vitro. A wellestablished BBB model based on PBECs co-cultivated with astrocytes 31 ( Fig. 2h and Supporting Information Fig. S3 ) was used to investigate trans-BBB migration of MB-231_Ctrl and MB-231_shA8 cells. In MB-231_shA8 cells, transmigration through the BBB was reduced by 57 6 4% compared to MB231_Ctrl cells (Fig. 2h) .
Transmigration of MB-231 cells is blocked by anti-ADAM8 and anti-PSGL-1 antibodies
Since ADAM8-dependent transmigration of MB-231 cells could be a process similar to transmigration of leukocytes, 26 we hypothesized that ADAM8 is able to cleave PSGL-1 in MB-231 cells to enable tumor cells the transmigration through an endothelial cell layer. Supernatants from MB- 231_Ctrl and MB-231_shA8 cells were analyzed for the formation of soluble PSGL-1 (sPSGL-1) by ELISA (Fig. 3a) . In comparison to WT cells, PSGL-1 release in the medium was reduced by at least 2.3-fold, suggesting that ADAM8 expression causes proteolytic release of sPSGL-1. Furthermore, we used MP inhibitors BB-94 and BB-2516 in MB-231_shCtrl cells to distinguish between ADAM8 and MMP-9 activities required for PSGL-1 shedding. Whereas BB-94 inhibits ADAM8 and MMP-9 very efficiently at concentrations of 500 nM, BB-2516 only inhibits MMP-9 when applied at 500 nM concentration. Thus we conclude that the reduction in ADAM8, but not in MMP-9 causes PSGL-1 shedding in MB-231 cells (Fig. 3a) . To determine the effect of soluble PSGL-1 (sPSGL-1) on transmigration of tumor cells through an endothelial layer, we investigated transmigration in the presence of antibodies directed against ADAM8 and sPSGL-1, respectively. Following transduction with shA8 scramble and shA8 knockdown lentivirus, SDF-1-dependent transmigration was dependent on the presence of ADAM8, as an ADAM8 knockdown caused a significant decrease in transendothelial migration (Figs. 3b and 3c ). The rate of transmigration caused by SDF-1 was significantly reduced by the addition of antibodies against ADAM8 (2.3 6 0.2-fold, p < 0.001) and against PSGL-1 (1.9 6 0.2-fold, p < 0.005) similar to the reduced transmigration determined for the ADAM8 knockdown construct (3.3-fold 6 0.5-fold, p < 0.001). From these data we conclude that ADAM8-dependent transmigration of MB-231 cells is dependent on the shedding of PSGL-1 by ADAM8. By confocal microscopy, we visualized the process of BBB transmigration of MB-231 cells in microdevices (Fig. 3d) . In a detailed view, Quantification of BBB transmigration of MB-231 shCtrl cells after inhibition of ADAM8, b1 integrin and MMP-9. As controls, IgG and control peptide (CP, no ADAM8 inhibition) was used. For ADAM8 inhibition, the ADAM8 inhibitor BK-1361 and the ADAM8 antibody was used in concentrations of 1 lM and 10 lg/ml, respectively. Control IgG and antibodies for b1 integrin and MMP-9 were used in concentrations of 10 lg/ml. Experiments were performed in triplicate in 3 independent experiments, data are presented as mean 6 SD with *, p < 0.01, **, p< 0.005, and ***, p < 0.001. cells penetrate the endothelial layer of the BBB with focal areas of proteolysis, degrading proteins of the endothelial layer such as tight junction proteins JAM-A, ZO-1, cadherin. We assume that in this process of transmigration, proteases other than ADAM8 might be involved. To explore the expression levels of MMP and other ADAM proteases in a knockdown of ADAM8, we performed microarray analyzes of MB-231_Ctrl and MB231_shA8 cells (two representatives for each cell line) using an Affimetrix gene chip. Amongst 23 ADAM genes, 24 MMP genes and four TIMP genes, reduction of ADAM8 caused exclusively a reduction of the mRNA levels of MMP-9 (Fig. 3e) .
Blood-brain barrier (BBB) transmigration in vitro is reduced by blocking ADAM8, MMP-9 and b1 integrin Accordingly, we investigated the effect of ADAM8 and MMP-9 on transmigration in the BBB model by using the ADAM8 inhibitory peptide BK-1361 and antibodies against ADAM8, MMP-9. In addition, we used a b1 integrin antibody as a positive control, because the effect of b1 integrin on transmigration was demonstrated previously 27, 32 (Fig. 3f ). As controls we used either cells treated with an inactive control peptide or with an irrelevant IgG control antibody. Both controls gave comparable results. In contrast, the antibodies against b1 integrin (AIIB2), ADAM8 (AF1031) and MMP-9 (AF911) caused a significant reduction in BBB transmigration (Fig. 3f) .
ADAM8 gene dosage in MB-231 cells affects MMP-9 expression
Reduced expression levels of MMP-9 as seen in the microarray were confirmed by qPCR in two representative cell clones (two controls, two knockdown, Fig. 4a) and on the protein level by western blot (Fig. 4b), gelatin zymography (Fig. 4c) and by activity assays based on computational inference 30 ( Fig. 4d) . We confirmed the reduced levels of MMP-9 in ADAM8 knockdown clones on the protein and activity level, respectively. To address the question whether this dependence of MMP-9 expression on ADAM8 levels, we tested the correlation of ADAM8 with MMP-9 in 29 brain metastases from different primary origins with high ADAM8 expression levels compared to non-neoplastic brain tissue (Fig. 4e) and in 12 different breast cancer cell lines (Supporting information Fig.  S4 ). The correlation of ADAM8 with MMP-9 in brain metastases, was shown to be highly significant (p 5 2.62 3 10
25
) with a Pearson correlation coefficient of 0.95, whilst correlation of ADAM8 with MMP-9 in breast cancer cell lines was 0.76 (p 5 0.0015). We conclude from these results that ADAM8 and MMP-9 are co-regulated in brain metastases and in breast cancer cell lines.
Signaling via CREB and ERK1/2 depends on ADAM8 CD
To analyze the signaling pathways associated with regulation of MMP-9, we next examined ADAM8-dependent kinase phosphorylation in a kinase array (Figs. 4f and 4g) . When comparing MB-231_Ctrl cells with MB-231_shA8 cells, phosphorylation levels of ERK1/2 and CREB were reduced in MB-231_shA8 cells, whereas phosphorylation levels of p70S6, Akt and MSK1/2 kinase were not significantly changed. By western blots, ADAM8-dependent phosphorylation of ERK1/ 2, CREB (S133) was confirmed (Fig. 4g) . We then used ADAM8 knockdown cells to re-express ADAM8 either as full-length ("A8 wt") protein or as protein lacking the cytoplasmic domain ("A8DCD") and analyzed ERK1/2 and CREB phosphorylation, respectively (Figs. 4h and 4i) . In a parallel experiment, the shedding activities of A8 wt and A8DCD were determined by CD23 ELISA analyses of cell lysates and supernatants; no differences in CD23 release were detected (Supporting Information Fig. S5 ). When ADAM8 lacking the cytoplasmic domain was re-expressed in MB-231 cells with ADAM8 knockdown, no difference to vector controls was observed. Immunofluorescence was performed to confirm membrane localization of ADAM8DCD (data not shown). When full-length ADAM8 was expressed in these cells, phosphorylation levels of ERK1/2 and CREB were increased by at least 2-fold (3.1 6 0.35-fold for CREB) and 2.2 6 0.3-fold for ERK1/2). In correlation with the phosphorylation state, expression levels of MMP-9 were affected in both MB231_shA8 cell lines (Fig. 4j) suggesting that the ADAM8-dependent phosphorylation levels of CREB and ERK1/2 affect MMP-9 expression levels significantly in MB-231 cells.
ADAM8-dependent transmigration and PSGL-1 shedding in Hs578t cells
The breast cancer cell line Hs578t (Hs578t wt) exerts a low endogenous expression level of ADAM8. In a "gain-offunction" type experiment, stable cell clones were generated with a moderate over-expression of ADAM8 (Hs578t_A8) and compared to a cell clone harboring an empty vector (Hs578t_Ctrl) confirmed by western blot (Fig. 5a ). All Hs578t cell clones were subjected to analysis of PSGL-1 shedding and transendothelial migration (Figs. 5be) . In Hs578t cells expressing ADAM8, a 7.5-fold (p < 0.001) increase of PSGL-1 shedding was determined (Fig. 5b) . To confirm a similar functional impact of PSGL-1 shedding as seen for MB-231 cells (Fig. 3) , transmigration assays were performed with Hs578t_Ctrl cells (Fig. 5c ) in the presence (Fig. 5c top) and absence (Fig. 5c bottom) of SDF-1. A significant increase in transmigration is observed upon stimulation by SDF-1 in these cells. However, when Hs578t_A8 cells were analyzed, a higher rate of transmigration was seen. Moreover, as shown for MB-231 cells (Figs. 2 and 3) , transmigration was reduced by inhibitory antibodies of ADAM8 and PSGL-1 and also by antibodies directed against b1 integrin and MMP-9 (Figs. 5d and 5e), whereas the respective IgG controls (goat IgG, mouse IgG) had no effect.
Discussion
Given the high frequency of ADAM8-positive metastases with >60% determined in clinical patient specimens we speculated that ADAM8 contributes to transmigration of tumor . Note that the decrease in protease activity is higher for MMP-9 than for ADAM8. (E) A total of 29 brain metastases (BC, n 5 10; SCLC, n 5 3; NSCLC, n 5 9; MM, n 5 7) and 5 control brain specimens (Ctrl, n 5 5) were analyzed for correlation of ADAM8 with MMP-9 mRNA expression. Pearson coefficient (r) and p values (p) are indicated and highly significant. (f) Comparative analysis of kinase phosphorylation using kinase profiler in shCtrl and shA8 cells. Samples were normalized based on protein concentration and reference signals included in the assay (g) Western blot analysis confirm results of kinase phosphorylation obtained in (f). (h) shA8 cells were transiently transfected in two independent experiments with DNA constructs expressing either ADAM8 full-length ("A8 wt") or ADAM8 DCD ("A8DCD") lacking the cytoplasmic domain or with empty vector ("Ctrl"). Following transfection, ADAM8 was detected by western blot and the extent of ERK1/2 (h) and CREB phosphorylation (i) was determined. (j) Effect of transient ADAM8 re-expression ("A8 wt") in shA8 cells on the expression levels of MMP-9 averaged over four independent experiments. Data are shown as mean values 6 SD with ***, p < 0.001 or not significant ("ns"). (k) Effect of transient ADAM8 expression in Hs578t breast cancer cells (low endogenous ADAM8 expression) on MMP-9 mRNA levels and phosphorylation of CREB and ERK1/2. Note that the western blots in (i) and (k) were trimmed from a larger blot, as marked by dotted grey lines.
cells that form metastases in distant organs. Thus, it is important to understand if tumor cells gain the expression of ADAM8 during metastasis formation. For selected patients we have tracked back ADAM8 expression levels in primary tumors and found ADAM8-positive tumor cells mainly in the invasive zone of primary breast tumors (Table 1 ). This finding demonstrates that ADAM8 expression is maintained during metastasis formation and metastases are rather enriched in ADAM8 suggesting that ADAM8 expression provides a selection advantage for tumor cells to metastasize. This finding is underlined by data showing that in a mouse model of breast cancer, circulating tumor cells (CTCs) express ADAM8 and cause a higher frequency of brain metastases. 27, 33 Functionally, by using an established organotypic BBB model in vitro 31, 34 we have demonstrated that ADAM8 is required for the transmigration of breast cancer cells through the BBB and to endothelial layers in vitro. In this process, shedding of surface ligands should occur in cis, that is, on the tumor cell surface, since HUVEC cells used in our experimental systems, express ADAM8 at a very low level in contrast to MB-231 cells (293-fold higher expression of ADAM8 in MB-231 vs. HUVEC cells).
We found that soluble PSGL-1 (sPSGL-1) released by ADAM8, but not by MMP-9, enables breast cancer cells to transmigrate through endothelia in both triple-negative breast cancer cell lines investigated. PSGL-1 is a major component of leukocyte rolling along endothelia 35 and can be considered as the initial step in transmigration when cells attach via PSGL-1/P-selectin interaction and detach via proteolytic PSGL-1 release from the endothelium. In a zebrafish model, the physiological relevance of PSGL-1 processing was recently demonstrated when ADAM8 is required for the onset of blood stream and for transmigration of red blood cells. 20 Similarly in metastasis formation, we conclude that the protease-substrate relationship between PSGL-1 and ADAM8, based on direct proteolytic release of soluble PSGL-1, is important for the initial step in brain metastasis of breast cancer cells.
In addition to PSGL-1 shedding, transmigration of tumor cells through the endothelial cell layer is promoted by proteolytic degradation of tight junction proteins. This particular step is likely mediated by proteolysis that requires MMPs 25 such as MMP-9. By regulating MMP-9, ADAM8 could also regulate this step of metastasis via transcriptional mechanisms involving ERK1/2 and CREB signaling. The positive correlation of ADAM8 and MMP-9 in 14 breast cancer cell lines and in 29 metastases from different primary origins provide evidence for a general regulatory effect of ADAM8 on MMP-9 transcriptional activation. In accordance, CREBdependent MMP-9 activation was reported previously in human non-small cell lung cancer cells by ICAM-3 to enhance their migratory and invasive potential 36 and the p38-MAPK signaling axis involving CREB and MMP-9 was further described in neutrophils associated with head and neck cancer. 37 Transmigration of circulating tumor cells is mediated by several factors, among them b1 integrin which can mediate adhesion of breast cancer cells to quiescent endothelial cells. 38 The role of b1 integrin in metastasis has been explored 39 and underlines the importance of integrin signaling in metastasis formation. In this respect it is interesting to note that ADAM8 can activate b1 integrin in tumor cells 32 and that MB-231 cells deficient in ADAM8 show a disturbed localization of b1 integrin on the cell surface suggesting that their adhesive behavior is significantly altered. This finding suggests that in addition to PSGL-1 shedding, ADAM8 can change the adhesive properties of MB-231 cells to endothelia by influencing b1 cell-surface localization and activation thereby changing the cell morphology into an invasive phenotype.
In the context of tumor cells, recent work has demonstrated that CREB can regulate transcription of the MMP-9 gene via upregulation of Adenylatcyclase 3 (ADCY3) in tumor cells 40 and by activation of the b2-adrenergic receptor that leads to ERK1/2 and subsequent CREB phosphorylation and enhanced MMP-9 transcription. 41 By using ERK1/2 inhibitor U0126, the authors showed that, similarly to our work, CREB activation occurs downstream of ERK1/2, as ERK1/2 inhibition abolished CREB activation. Furthermore, recent work on MB-231_ctrl and MB-231_shA8 cells demonstrated that ADAM8 can regulate miRNAs such as miRNA-720. 33 It remains to be determined if miRNAs affected by ADAM8 expression, such as miRNA720, can also regulate MMP-9 expression levels.
In conclusion, we have demonstrated that ADAM8 promotes two steps in the process of brain metastasis of breast cancer cells. In the first step "leukocyte mimicry" of tumor cells, interaction between P-selectin and the ligand PSGL-1 is modulated by ADAM8-dependent cleavage of PSGL-1. In the second step, MMP-9 transcription is activated by ERK1/2 and CREB and leads to enhanced extracellular proteolysis. Thus, it is likely that the co-regulation of MMP-9 in conjunction with ADAM8 protease activity is one important mechanism for the formation of brain metastases. Clinically, our data indicate that ADAM8 might be a good predictor for metastasis and it remains to be determined in more studies, how ADAM8 expression levels in breast cancer and the occurrence of metastases are correlated.
